Read
- French soldier stabbed while on patrol near Paris
- REPEAT-Will immigration reform get killed in Republican-led U.S. House?
- Planetary alignment peaks with celestial show this weekend
- Two believed dead as heavy rains flood San Antonio streets
|
- Two freight trains collide in Missouri, bringing down overpass
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Sponsored Links
BioMimetic submits more data on bone graft product
(Reuters) - BioMimetic Therapeutics Inc said it submitted additional data sought by health regulators for the marketing approval of the company's bone graft product, sending its shares up 14 percent after the bell.
The biotechnology company said it filed an amended application saying that the bone graft product, Augment, is not inferior to autograft.
The Food and Drug Administration in January declined to approve marketing of BioMimetic's bone graft product and asked for additional safety and efficacy data from a late-stage trial.
The Franklin, Tennessee-based company expects a final decision from the regulator between April 2013 and January 2014, even if the FDA had a second round of questions.
BioMimetic shares, which have lost about 40 percent of their value so far this year, were up 14 percent at $3.19 after the bell. They closed at $2.80 on Monday on the Nasdaq.
(Reporting by Prateek Kumar in Bangalore; Editing by Don Sebastian)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters